Skip to main content

Advertisement

SpringerLink
Log in

Atopic diseases

The hype and hope of new food allergy treatments

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Food allergy treatment is undergoing a paradigm shift with new therapies emerging, including the recent FDA approval of omalizumab — but without evidence of disease modification and with uncertain quality-of-life improvement, it may not be a panacea for all.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Food allergen thresholds with omalizumab and placebo in the OUtMATCH study.

References

  1. Wood, R. A. et al. N. Engl. J. Med. 390, 889–899 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. US Food and Drug Administration. FDA https://go.nature.com/3JgRn05 (16 February 2024).

  3. Hippocrates. Ancient Medicine (transl. Jones, W. H. S.) (G. P. Putnam, 1931).

  4. Schofield, A. Lancet 171, 716 (1908).

    Article  Google Scholar 

  5. The PALISADE Group of Clinical Investigators. N. Engl. J. Med. 379, 1991–2001 (2018).

    Article  Google Scholar 

  6. Palforzia. https://palforziarems.com/#Main/Home (accessed 26 March 2024).

  7. Australasian Society of Clinical Immunology and Allergy. https://go.nature.com/3TWewK7 (accessed 26 March 2024).

  8. Chu, D. K. et al. Lancet 393, 2222–2232 (2019).

    Article  CAS  PubMed  Google Scholar 

  9. Perrett, K. P., Sindher, S. B., Begin, P., Shanks, J. & Elizur, A. J. Allergy Clin. Immunol. Pract. 10, 19–33 (2022).

    Article  CAS  PubMed  Google Scholar 

  10. Leung, D. Y. P. et al. N. Engl. J. Med. 348, 986–993 (2003).

    Article  CAS  PubMed  Google Scholar 

  11. Zuberbier, T. J. Allergy Clin. Immunol. Pract. 11, 1134–1146 (2023).

    Article  CAS  Google Scholar 

  12. Hwang, D. W., Nagler, C. R. & Ciaccio, C. E. Immunother. Adv. 2, ltac006 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

K.P.P. is supported by a National Health and Medical Research Council (Australia) fellowship (GNT2008911) and a Melbourne Children’s Clinician–Scientist Fellowship. Research at Murdoch Children’s Research Institute is supported by the Victorian Government’s Operational Infrastructure Support Program.

Author information

Authors and Affiliations

  1. Population Allergy Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia

    Kirsten P. Perrett

  2. National Allergy Centre of Excellence, Parkville, Victoria, Australia

    Kirsten P. Perrett

  3. Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia

    Kirsten P. Perrett

  4. Department of Allergy and Immunology, Royal Children’s Hospital, Parkville, Victoria, Australia

    Kirsten P. Perrett

Authors
  1. Kirsten P. Perrett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kirsten P. Perrett.

Ethics declarations

Competing interests

K.P.P. has received research grants from Aravax, DBV Technologies, Novartis and Siolta and consultant fees from Aravax, paid to their institution, outside the submitted work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Perrett, K.P. The hype and hope of new food allergy treatments. Nat Med (2024). https://doi.org/10.1038/s41591-024-02952-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41591-024-02952-5

  • Springer Nature America, Inc.

Search

Navigation